Sunday, June 14, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 273 of 1,261
  1. US 11291672

    Betamethasone oral spray formulation and method of use to treat ataxia

    GRACE THERAPEUTICS INC. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  2. US 11291681

    Method for treating fibrotic liver tissue using Cl-IB-MECA

    CAN-FITE BIOPHARMA LTD. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  3. US 11291659

    P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

    Fulcrum Therapeutics, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  4. US 11291653

    Compounds and methods for treating an epileptic disorder

    The Regents of the University of California · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  5. US 11291658

    Use of gaboxadol in the treatment of diabetes and related conditions

    OVID THERAPEUTICS INC. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  6. US 11291657

    Methods of treating inflammatory bowel disease with AMD3100 and Tacrolimus

    MedRegen, LLC · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  7. US 11291636

    Polymer protein microparticles

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  8. US 11292847

    Methods for treating atopic dermatitis by administering an IL-4R inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  9. US 11292842

    Anti-PD-1 antibodies for treatment of lung cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  10. US 11293009

    Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

    Iovance Biotherapeutics, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  11. US 11292778

    Heterocyclyl polymethine IR chromophores

    The Regents of the University of California · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  12. US 11291697

    Probiotic composition and use thereof

    INFINITUS (CHINA) COMPANY LTD. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  13. US 11292766

    Substituted piperidine compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  14. US 11291407

    Detection of high risk drusen

    Apellis Pharmaceuticals, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  15. US 11292815

    Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods

    Apellis Pharmaceuticals, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  16. US 11292758

    Compounds and methods for delivery of prostacyclin analogs

    United Therapeutics Corporation · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  17. US 11291728

    Anhydrous sodium thiosulfate and formulations thereof

    Fennec Pharmaceuticals, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  18. US 11293024

    Antisense antibacterial compounds and methods

    The Board of Regents of the University of Texas System · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  19. US 11293025

    Compositions and methods for modulating Ataxin 3 expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  20. US 11292835

    Low dose antibody-based methods for treating hematologic malignancies

    Actinium Phamaceuticals, Inc. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  21. US 11291639

    Dosage forms and methods for enantiomerically enriched or pure bupropion

    AXSOME THERAPEUTICS, INC. · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  22. US 11291662

    Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

    Vertex Pharmaceuticals Incorporated · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  23. US 11291709

    Pharmaceutical compositions and methods for fabrication of solid masses comprising TNF-inhibiting antibodies

    Rani Therapeutics, LLC · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted
  24. US 11293010

    Methods of producing modified natural killer cells and methods of use

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 5, 2022 · Expires Mar 31, 2042

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.